Néovacs: Its Anti-Allergy mRNA Vaccine AllergyVacs2 Highlighted by the ANR
Néovacs' 'AllergyVacs2' program, developed in partnership with INSERM, has been spotlighted by the National Research Agency during the European Vaccination Week. The project, funded by a grant of over €600,000, aims to create an mRNA vaccine against severe allergic diseases.
A Therapeutic Vaccine Project for Severe Forms of Allergy
The 'AllergyVacs2' program, jointly carried by Néovacs and Dr. Laurent Reber's INSERM team at the Toulouse Institute of Infectious and Inflammatory Diseases (Infinity), seeks to develop an anti-IgE mRNA vaccine capable of preventing certain allergic diseases and their most severe manifestations.
According to the World Health Organization, nearly 30% of the population suffers from allergies, with a prevalence expected to reach 50% by 2050. Current treatments control symptoms but do not address the cause sustainably. The project explores mRNA-based vaccine approaches aimed at long-term action while improving patient comfort and reducing treatment costs.
Preliminary Preclinical Results and Next Steps
The initial preclinical results are described as promising and have demonstrated the proof of concept of a first vaccine candidate in protecting against anaphylactic shock, the most severe manifestation of allergy.
Several important steps remain necessary to select the final candidate with an optimal efficacy and safety profile for clinical development. Néovacs highlights that this program benefits from the expertise of its teams through the development of its dedicated mRNA platform for treating allergies.
